Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Addaction

- PMLiVE

It’s on: Shire and AbbVie agree £32bn takeover

Companies agree deal that is set to cut US pharma company’s corporate tax bill

- PMLiVE

Olysio leads charge at J&J but competition is on the way

CEO Gorsky warns that Gilead’s Sovaldi will impact sales of hepatitis C drug

- PMLiVE

AbbVie coaxes Shire into discussions with sweetened offer

Raises takeover bid to $53bn

- PMLiVE

US senators seeks answers on Sovaldi pricing

Gilead asked to justify pricing of hepatitis drug

- PMLiVE

AbbVie raises Shire bid to £30bn

Latest offer is company’s fourth attempt at takeover

- PMLiVE

AbbVie takes PARP inhibitor into third phase III trial

Veliparib under investigation for use in advanced breast cancer

- PMLiVE

Janssen-backed report calls on governments to tackle hepatitis C

Report finds that national policies do not adequately address disease

Shire Basingstoke

Shire spells out why AbbVie takeover is a bad idea

Talks up its growth prospects as an independent company

- PMLiVE

Boehringer pulls faldaprevir and exits hepatitis C market

Unable to challenge all-oral options from Gilead and others

Shire Basingstoke

Shire turns down takeover offer from AbbVie

Marks third time UK pharma company has turned down AbbVie's advances

Gilead Sciences

Sovaldi stumbles as NICE assesses hep C drug’s price

Gilead must provide much more cost-effectiveness information

AbbVie closes in on US approval of all-oral hepatitis C regimen

FDA grants priority review to company’s protease inhibitor ABT-450 regimen

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links